Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SST-0225 is a patented topical cream formulation of ibuprofen developed for the treatment of acute pain, including delayed onset muscle soreness (DOMS), myalgia, and ankle injuries. It utilizes Strategic Science & Technologies' proprietary KNOSIS delivery technology to enhance local tissue penetration of ibuprofen while minimizing systemic absorption. This targeted delivery aims to provide rapid pain relief with reduced risk of systemic side effects compared to oral NSAIDs. Clinical trials have demonstrated that SST-0225 is safe and well-tolerated, offering potential advantages such as faster onset of action and improved safety profile over traditional oral formulations[1][4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SST-0225.